Peripheral nerve entrapment: an unusual adverse event with high-dose interleukin-2 therapy.

@article{Sikora1996PeripheralNE,
  title={Peripheral nerve entrapment: an unusual adverse event with high-dose interleukin-2 therapy.},
  author={Sadiq Saleem Sikora and Maxim Samsonov and Keith A Dookeran and Howard D. Edington and Michael T Lotze},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={1996},
  volume={7 5},
  pages={
          535-6
        }
}
Recombinant interleukin 2 (rIL-2) is a promising biological therapy agent in the treatment of patients with metastatic renal cell carcinoma and metastatic melanoma [1, 2]. The antitumor effects are a result of a complex interplay of generation of NK and T-cells and secretion of a variety of lymphokines (IFN, IL6 and TNF) [3]. Early studies and success with rIL-2 were reported with the high dose intravenous bolus administration regimen [4-6]. High dose rIL-2 therapy is associated with… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-2 OF 2 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-9 OF 9 REFERENCES

Biologic therapy with interleukin-2: Preclinical studies

MT Lotze
  • Philadelphia: JB Lippincott Company
  • 1995
VIEW 1 EXCERPT

Randomised comparison of high dose and low dose intravenous interleukin-2 for the therapy of metastatic renal cell cancer An interim report

JC Yang, SL Topalian, D Parkinson
  • J Clin Oncol
  • 1994
VIEW 1 EXCERPT

Interleukin-2: Clinical applications

MT Lotze, SA Rosenberg
  • Philadelphia: JB Lippincott Company
  • 1992
VIEW 1 EXCERPT